ALAMERE: A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study with an Open-Label Extension to Investigate the Efficacy and Safety of Solrikitug in Adults with Esophagitis ( ALAMERE)

A drug called solrikitug is being tested in a Phase 2 clinical trial to see if it can stop the immune attack that makes swallowing painful for people with eosinophilic esophagitis (EoE). In EoE, a type of white blood cell builds up in the oesophagus, causing inflammation, scarring, and narrowing that makes food get stuck. Current treatments—steroids or strict elimination diets—are burdensome and often ineffective long-term. Solrikitug works by blocking TSLP, a protein that acts as an early trigger for the allergic immune cascade driving the disease. By intercepting this signal at the top of the chain, the drug aims to quiet the entire inflammatory response rather than treating symptoms downstream. If the trial shows solrikitug is safe and effective, it could offer EoE patients a targeted, injection-based therapy that replaces daily steroids or extreme dietary restrictions. For a condition that primarily affects children and young adults, a treatment that reduces the risk of oesophageal narrowing and emergency food impactions would be a meaningful shift in disease management. The open-label extension will also provide early data on long-term safety and durability of response.